Best Recombinant Proteins CDMOs by Signal Score

← All Recombinant Proteins CDMOs Best Clean FDA History Commercial Scale
10
CDMOs tracked
10
Fully scored
4
With FDA records
13
FDA inspections
65
EMA/MHRA GMP certs
2
Warning letters

Recombinant protein CDMOs make therapeutic proteins, enzymes, and growth factors using microbial (E. coli, yeast) or mammalian (CHO) expression. Choice of host turns on post-translational modification needs, scale economics, and downstream-purification complexity.

Selecting a recombinant protein CDMO turns on host-system experience, validated bioreactor scale, downstream purification and analytics, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 3 NAI (no action), 9 VAI (voluntary action), 1 OAI (official action). Leading inspection & GMP sites: Germany (25), United States (12), Lithuania (8), UNITED KINGDOM (8), UNITED STATES (8).

Last updated 2026-06-29. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

# CDMO Signal Score Quality FDA · GMP Capacity Programs
1
KB
KBI Biopharma
Durham, NC · Boulder, CO
 83.5 100.0 1 insp · 1 GMP Limited 0 programs
2
RB
Richter BioLogics
Hamburg, Germany
 82.9 100.0 0 insp · 9 GMP — 0 programs
3
WK
Wacker Biotech
Jena, DE · Amsterdam, NL · San Diego, CA
 81.6 100.0 0 insp · 13 GMP — 0 programs
4
NW
Northway Biotech
Vilnius, LT; Waltham (MA), USA
 80.8 100.0 0 insp · 8 GMP Available 0 programs
5
RB
Rentschler Biopharma
Laupheim, Germany
 79.9 99.3 1 insp · 2 GMP — 0 programs
6
Catalent
Somerset, NJ (now operating under Novo Holdings, HQ effectively Bagsværd, Denmark)
 76.5 79.3 10 insp · 32 GMP — 0 programs
7
CA
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
 75.1 79.3 1 insp · 0 GMP Available 0 programs
8
SB
Samsung Biologics
Incheon, South Korea
 68.5 — — — 0 programs
9
Cytovance Biologics
Oklahoma City, OK
 61.5 — — Available 0 programs
10
BN
Bionova Scientific
Fremont, CA
 59.0 — — — 0 programs
How we score CDMOs →

What to evaluate in a Recombinant Proteins CDMO

Expression host & scale
Microbial hosts (E. coli, P. pastoris) suit non-glycosylated proteins; mammalian (CHO) is the workhorse for glycoproteins. Confirm validated bioreactor scale and the CDMO's experience with your target.
Purification & analytics
Downstream complexity (multiple chromatography steps, refolding for E. coli) drives cost and timeline. Ask about the orthogonal analytics package — purity, identity, potency.
Regulatory readiness
Clean FDA 483 history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & commercial readiness
For programs heading to BLA, evaluate validated commercial scale and any approved-product track record.

Recombinant Proteins CDMOs — Frequently Asked Questions

Who are the top Recombinant Proteins CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Recombinant Proteins CDMOs include KBI Biopharma, Richter BioLogics, Wacker Biotech. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Recombinant Proteins CDMOs have FDA inspection records?
CDMO Signal tracks 4 Recombinant Proteins CDMOs with FDA inspection records and 65 EMA/MHRA GMP certificates across the group.
What should I look for in a recombinant protein CDMO?
Confirm expression-host experience for your target (microbial vs mammalian), validated bioreactor scale, a strong downstream-purification platform, qualified analytics, and a clean FDA and EMA/MHRA record.
How is a recombinant protein CDMO different from a mAb CDMO?
There's significant overlap — mAbs are recombinant proteins. But mAb CDMOs are typically optimized for CHO-based platform processes, while general recombinant protein CDMOs handle a wider range of hosts and non-mAb formats (enzymes, growth factors, complex non-glycoproteins).
Related modalities
Biologics / mAb CDMOs mRNA / LNP CDMOs Cell Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome ADC